NCT04865653View on ClinicalTrials.gov

LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

October 11, 2023

Study Completion Date

October 11, 2023

Conditions
Healthy
Interventions
DRUG

Lysergic Acid Diethylamide Base oral drinking solution

A moderate dose of 0.1 mg LSD will be administered.

DRUG

Lysergic Acid Diethylamide Base solid orodispersible film

A moderate dose of 0.1 mg LSD will be administered.

DRUG

Lysergic Acid Diethylamide Tartrate oral drinking solution

A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

DRUG

Lysergic Acid Diethylamide Tartrate intravenous administration

A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

OTHER

LSD Placebo

Placebo for each formulation containing only the solvent or gel but no LSD.

Trial Locations (1)

4031

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER